Third, we also identified a relatively large proportion of gene mutations, like P2RY8 (14/53), LRP1B (8/53), B2M (7/53), BCR (6/53), that seldom mentioned by other DLBCL sequencing studies but may probably become the oncogenic events by modulating the B cell migratory behavior and signaling activation [27, 28]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.